reports
Kane Biotech Announces Closing of Private Placement Offering with an I...
Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces that today it has completed its previously announced non-brokered private placement offering (the “Offering”) of common shares of the Company (“Shares”). At the closing of the Offering, Kane issued 14,000,000 Shares at a price of $0.05 per Share for gross proceeds of $700,000 t...
Kane Biotech Presents New Data at Innovations in Wound Healing Annual ...
Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting WINNIPEG, Manitoba, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) announces that it presented new clinical and scientific data at the Innovations in Wound Healing (“IWH”) Annual Meeting, which took place in Key West, Florida December 11-14, 2025. At this year’s conference, Kane Biotech shared case study data from across its wound care portfolio, underscoring the company’s commitment to addressing complex and high-burden health conditions. The link to ...
Kane Biotech Receives Health Canada Approval for revyve® Antimicrobial...
Kane Biotech Receives Health Canada Approval for revyve® Antimicrobial Wound Gel Spray WINNIPEG, Manitoba, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that Health Canada has approved its revyve® Antimicrobial Wound Gel Spray for use in Canada. Health Canada approved revyve Antimicrobial Wound Gel Spray revyve Antimicrobial Wound Gel Spray has been previously cleared under the FDA 510(k) process. This Health Canada approval represents another regulatory milestone for Kane and the Company’s commitment to advan...
Kane Biotech Announces Third Quarter 2025 Financial Results
Kane Biotech Announces Third Quarter 2025 Financial Results WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced its third quarter 2025 financial results. Third Quarter 2025 Financial Highlights (Comparatives exclude discontinued STEM Animal Health “STEM” Operations): Total revenue for the three months ended September 30, 2025 was $8,499 compared to $1,282,698 in the three months ended September 30, 2024. The vast majority of revenue recorded in the comparative quarter was related to an animal healt...
Kane Biotech Announces New Private Placement Offering
Kane Biotech Announces New Private Placement Offering Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its intention to undertake a non-brokered private placement offering (the “Offering”) of up to 16 million common shares (“Shares”) at a price of $0.05 per Share for gross proceeds of up to $800,000. The net proceeds of the Offering will be used for working capital and general corporate purposes. Certain inside...
Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Regio...
Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences Average Percent Area Reduction of 97% in 4 weeks in diabetic wounds100% diabetic wound closure in ≤ 12 weeksPreclinical sustained antibiofilm activity for a minimum of 7 days WINNIPEG, Manitoba, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane Biotech” or “Kane”) today announced new clinical and pre-clinical data demonstrating the performance of its FDA-cleared revyve® Antimicrobial Wound Gel and revyve Wound Gel Spray in both diabetic foot ulcer healing and burn wound infectio...
Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicr...
Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser WINNIPEG, Manitoba, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has completed a U.S. Food and Drug Administration (“FDA”) 510(k) clearance submission for its revyve® Antimicrobial Wound Cleanser. revyve Antimicrobial Wound Cleanser is the Company’s third product in its revyve product line and complimentary to Kane’s revyve Antimicrobial Wound Gel and Antimicrobial Wound Gel Spray products. This new companion product will...
Kane Biotech Completes Enrollment in U.S. Case Series Studies of its r...
Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray WINNIPEG, Manitoba, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) today announces that it has enrolled 28 participants in its revyve® Antimicrobial Wound Gel and Spray U.S. Case Series Studies, exceeding its 25-participant target. US FDA 510(k) cleared revyve Antimicrobial Wound Gel For the clinical series, Kane engaged wound care and burn specialists in the U.S. Data is anticipated to be presented at various medical m...
Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced...
Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Fall Conference Clinical data to be presented demonstrates wound healing in complex wounds that were over two years old WINNIPEG, Manitoba, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that Interim Chief Executive Officer, Dr. Robert Huizinga, will be presenting at the Symposium on Advanced Wound Care (“SAWC”) Fall conference taking place from September 3-6, 2025 in Las Vegas, Nevada. US FDA 510(k) cleared revyve An...
Kane Biotech Announces Second Quarter 2025 Financial Results
Kane Biotech Announces Second Quarter 2025 Financial Results WINNIPEG, Manitoba, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced its second quarter 2025 financial results. Second Quarter 2025 Financial Highlights (Comparatives exclude discontinued STEM Animal Health “STEM” Operations): Total revenue for the three months ended June 30, 2025 was $27,997 compared to $620,437 in the three months ended June 30, 2024. Almost all revenue recorded in the comparative quarter was related to the Company’s animal health busin...
Kane Biotech Showcases revyve™ Preclinical and Clinical Case Study Fin...
Kane Biotech Showcases revyve™ Preclinical and Clinical Case Study Findings at North American Wound Care Conferences Clinical case series showed clinically meaningful reductions in wound size and pain, and improved tissue regranulation in chronic wound patients using revyve® over 6–12 weeks Preclinical in vitro studies demonstrated >80% reduction in protease activity, including complete inhibition of TACE and collagenase — key factors in non-healing chronic wounds revyve® data featured in presentations and posters at NSWOCC and SAWC—two of the leading North American conferences on wound c...
Kane Biotech to Present at Advanced Wound Care Summit USA
Kane Biotech to Present at Advanced Wound Care Summit USA WINNIPEG, Manitoba, July 14, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane Biotech” or “Kane”) announces today that Kane Biotech’s Interim Chief Executive Officer, Dr. Robert Huizinga, will be presenting at the 4th Advanced Wound Care Summit USA taking place from July 15-17, 2025 in Boston, MA. The Advanced Wound Care Summit USA is an industry gathering dedicated to the business of wound care where innovators, payers, regulators, and multinational leaders come together to turn breakthrough science into profitable,...
Kane Biotech Provides Further Corporate Update
Kane Biotech Provides Further Corporate Update WINNIPEG, Manitoba, June 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) provides updates on its reorganizational phase. The Company has terminated its exclusive distribution agreement with ProgenaCare Global LLC (“ProgenaCare”) dated April 18, 2023 due to various material breaches by ProgenaCare of the agreement. Activities to resecure distribution for its products in the United States are underway. The Company recently received a notice of default from Prairies Economic Development ...
Kane Biotech Announces First Quarter 2025 Financial Results
Kane Biotech Announces First Quarter 2025 Financial Results WINNIPEG, Manitoba, May 29, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its first quarter 2025 financial results. First Quarter 2025 Financial Highlights (Comparatives Exclude Discontinued STEM Animal Health “STEM” Operations): Total revenue for the three months ended March 31, 2025 was $412,513 compared to $51,886 in the three months ended March 31, 2024. Revenue in the current quarter consists primarily of contract animal health manufacturing revenue for...
Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Res...
Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change WINNIPEG, Manitoba, April 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announced its fourth quarter and full year 2024 financial results. Fourth Quarter 2024 Financial Highlights (Comparatives Exclude Discontinued STEM Animal Health “STEM” Operations): Total revenue for the three months ended December 31,2024 was $125,859 compared to $57,788 in the three months ended December 31, 2023. F...
Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acn...
Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial Kane to work with the University of Miami to study DispersinB® Acne Cleanser in mild to moderate Acne Vulgaris WINNIPEG, Manitoba, March 13, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) ("Kane Biotech" or "Kane") announces today that it has received approval from the Internal Review Board (“IRB”) of the University of Miami Health System (“UHealth”) to commence a clinical study of Kane’s prototype DispersinB® Acne Cleanser for the treatment of mild to moderate cases of Acne Vulgaris. The ...
Kane Biotech Announces Canadian Distribution Agreement With Best Buy M...
Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel Strategic Partnership Expands Access to Innovative Wound Care Solution Across Canada WINNIPEG, Manitoba, March 11, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (“Kane Biotech”) announces that it has concluded a three-year distribution agreement with Best Buy Medical Canada for its revyve™ Antimicrobial Wound Gel Product line. In November 2024, Kane Biotech received Health Canada approval for its revyve™ Antimicrobial Wound Gel, marking a significant...
Kane Biotech Inc: 2 directors
Two Directors at Kane Biotech Inc bought/subscribed to 2,600,000 shares at 0.100CAD. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
Kane to Host Investor Webinar – What Kane has in Store for 2025 Includ...
Kane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB Dermatology Thursday, January 23rd, 2025 at 4:15pm Eastern Time WINNIPEG, Manitoba, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday, January 23, 2025 at 4:15pm Eastern Time. Participants can register for the webinar by using this link: Marc Edwards, President and CEO, along with Dr. Robert Huizinga, Executive Chairman will update investors as to what they should expect in 2025, building on th...
Kane Biotech Announces First Closing of Private Placement Offering and...
Kane Biotech Announces First Closing of Private Placement Offering and Extension of Private Placement Offering Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces that today it has completed the first closing of its previously announced non-brokered private placement offering (the “Offering”) of common shares of the Company (“Shares”). At the first closing Kane issued 12,750,000 Shares at a price of $0.10 per...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.